Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients
NCT03007225 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2020-10-22
Summary
This study aimed to to compare the conventional transarterial chemoembolization (cTACE) with chemoembolization using doxorubicin drug eluting beads (DEB-TACE) for the treatment of hepatocellular carcinoma regarding short term efficacy and safety in first 3 months after embolization
Conditions
Interventions
- DRUG
-
Trans-arterial chemoembolization (TACE)
TACE procedures were performed by experienced radiologists by fluoroscopy. The femoral artery was catheterized under local anesthesia, with a 4F catheter with Copra head configuration. Conventional angiography of the Coeliac and Hepatic arteries to delineate the feeding arteries of the tumors and to exclude portal venous shunting. Then vascular catheter was inserted super-selectively into the branch of the hepatic artery that is the main feeder of the tumor. Chemoembolization then was performed. Ten milliliters of Lipiodol was mixed with 100 mg of Doxorubicin hydrochloride and 5ml of Urografin emulsified to create a milky solution. The emulsion slowly was infused into the tumour Gel foam embolization was performed by cutting gel foam sheets into small pledges mannully then mixed with a contrast material and an impirical antibiotic (gentamycin 80 mg). Injection of the mixture slowly under fluoroscopy guidance till complete stasis was achieved.
- DRUG
-
TACE with Drug Eluting Beads procedure
The same was done as cTACE till the super selective catheterization of the feeding artery. Loading of the beads with Doxorubicin hydrochloride (100-150 mg) was done in vitro an hour before the beginning of catheterization. The loaded beads were then aspirated from the vial into a syringe filled with nonionic contrast medium. Once the feeding artery was identified and catheter was in placement, the loaded beads were infused slowly under fluoroscopic guidance. Two different sizes of DC beads were used, 100-300 μm and 300-500. Starting with the smaller sized beads to occlude the tumoral bed followed by the larger sized one to embolize the proximal vessels. The injection of the loaded beads was performed as selective as possible using either a4F diagnostic catheter (Cobra head catheter; Cordis, USA) or 2.7F microcatheter (Progreat; Terumo, Japan).
Sponsors & Collaborators
-
Ain Shams University
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-07-31
- Primary Completion
- 2016-08-31
- Completion
- 2016-08-31
More Related Trials
-
DEB-TACE for Hepatocellular Carcinoma
NCT02748161 ·Status: TERMINATED ·Phase: NA
-
Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion
NCT00826384 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC)
NCT06023147 ·Status: UNKNOWN ·Phase: NA
-
The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
NCT05862181 ·Status: UNKNOWN
-
Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis
NCT03007212 ·Status: COMPLETED ·Phase: PHASE4
-
Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC
NCT02670122 ·Status: COMPLETED
-
Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma
NCT01798134 ·Status: COMPLETED ·Phase: NA
-
DEB-TACE vs cTACE in HCC After TIPS
NCT07322848 ·Status: RECRUITING ·Phase: PHASE3
-
Role of DEB-TACE Versus c-TACE in Treatment of HCC
NCT05093920 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
DEB-TACE Versus DEB-TACE Sequential HAIC for Unresectable BCLC Stage C HCC; A Randomized Controlled Trial
NCT05788835 ·Status: RECRUITING ·Phase: NA
-
TACE as an Adjuvant Therapy After Hepatectomy for HCC
NCT01966133 ·Status: UNKNOWN ·Phase: PHASE3
-
DEB-TACE Treatment in 367 Liver Cancer Patients
NCT03317483 ·Status: COMPLETED
-
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC
NCT05332821 ·Status: COMPLETED
-
DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC
NCT04967482 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study
NCT04975932 ·Status: COMPLETED
-
TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients
NCT01409733 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
NCT04712643 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve
NCT02147301 ·Status: TERMINATED ·Phase: NA
-
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
NCT06024252 ·Status: UNKNOWN
-
Traditional (Traditional Chemoembolization) TACE Versus Microsphere TACE
NCT00936689 ·Status: COMPLETED ·Phase: PHASE4
-
TACE for HCC by TANDEM and Idarubicin
NCT03349957 ·Status: COMPLETED
-
Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin
NCT03259581 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
NCT07239245 ·Status: RECRUITING ·Phase: PHASE2
-
TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
NCT04954781 ·Status: RECRUITING ·Phase: PHASE2
-
Drug-eluting Bead in Hepatocellular Carcinoma
NCT01332669 ·Status: COMPLETED ·Phase: PHASE4